Stockreport

Kura Oncology: Commercialization In AML Presents Asymmetric Upside [Seeking Alpha]

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF KURA's 2026 revenue expectations are achievable, requiring only 16% market penetration in NPM1-m R/R AML, supported by rapid payer coverage and favorable launch dynamic [Read more]